VK2735 Maintenance Data: Dosing Flexibility Signal Is Real, But 12-Week Evidence Cannot Carry Pivotal Weight

VK2735 Maintenance Study Shows Strong Weight Loss Retention

Viking Therapeutics reported positive topline results from its maintenance study of VK2735, a dual GLP-1/GIP receptor agonist for obesity. The study demonstrated superior weight maintenance with less frequent subcutaneous dosing regimens (monthly and every-other-week) compared to placebo. Participants on every-other-week dosing maintained up to 97% of their mean weight loss, while those on monthly dosing maintained up to 90%, significantly outperforming placebo's 61%. The drug also showed excellent tolerability during the 12-week maintenance phase, with gastrointestinal adverse event rates comparable to placebo. These results support VK2735's potential for flexible, long-term weight management.

• Robust Weight Loss Maintenance with Flexible Dosing: VK2735 demonstrated superior weight loss maintenance during the 12-week maintenance phase. Subjects transitioned to every-other-week dosing maintained up to 97% of their mean weight loss achieved during the induction period, while those on monthly dosing maintained up to 90%. Both regimens significantly outperformed placebo, which showed 61% weight loss maintenance (p<0.0001 for every-other-week combined, p=0.0002 for monthly combined vs. placebo). This highlights the potential for less frequent administration to sustain weight loss.
• Significant Initial Weight Reduction: During the preceding 21-week induction phase, participants receiving weekly VK2735 achieved substantial weight loss, ranging from approximately 16% to 19% from baseline, compared to approximately 0% for placebo (p<0.0001 for all VK2735 cohorts vs. baseline and placebo). An exploratory control arm continuing weekly VK2735 dosing showed progressive weight loss, reaching approximately 22% from baseline after 33 weeks, indicating no plateau in efficacy with longer-term weekly administration.
• Favorable Safety and Tolerability Profile: VK2735 exhibited excellent tolerability during the maintenance phase, with rates of GI-related adverse events (such as nausea, vomiting, diarrhea, and constipation) not meaningfully different from placebo. Discontinuation rates, including those due to adverse events, were low throughout both the induction and maintenance portions of the trial. This encouraging safety profile, consistent with prior studies, supports the drug's potential for long-term use in obesity management.

Addressing the Challenge of Long-Term Weight Management in Obesity

Obesity management remains one of the most complex challenges in modern medicine, with no single treatment modality offering a universally durable solution. Current approaches — spanning lifestyle intervention, pharmacotherapy, and bariatric surgery — each carry distinct limitations that impede long-term success across diverse patient populations.

• Weight regain following pharmacotherapy discontinuation. GLP-1 receptor agonist discontinuation produces significant metabolic rebound: among individuals with obesity, body weight increases by 5.63 kg (95% CI: 3.52–7.73) and HbA1c rises by 0.25% (95% CI: 0.18–0.32) post-cessation. In the STEP 1 trial extension, participants regained two-thirds of prior weight loss within one year of withdrawing semaglutide 2.4 mg, with cardiometabolic improvements reverting towards baseline — confirming that pharmacotherapy requires sustained adherence to maintain therapeutic gains.

• Gastrointestinal adverse effects limiting adherence. GI side effects are common across anti-obesity medications, particularly GLP-1 receptor agonists such as semaglutide and tirzepatide, especially during dose escalation. A meta-analysis of semaglutide in nondiabetic adults found treatment discontinuation due to adverse events was significantly higher in the semaglutide group (RR 2.62, 95% CI: 1.70–4.03; P = .001), with nausea, vomiting, diarrhea, and constipation as the most commonly reported events.

• Physiological counter-regulatory mechanisms driving weight cycling. Weight regain after loss is driven by physiological counter-regulatory mechanisms — decreased energy expenditure, increased energy intake, and impaired brain-periphery communication — that actively preserve energy. Emerging evidence implicates epigenetic mechanisms, including histone modifications and DNA methylation, as contributors to an "obesogenic memory" that undermines long-term weight loss maintenance.

• Access and insurance barriers to both pharmacotherapy and surgery. Concerns regarding costs and insurance coverage represent a shared barrier to long-term antiobesity medication use for both people with obesity and healthcare providers. Bariatric surgery, despite its effectiveness, is accessed by only 1% of the currently eligible population — roughly 228,000 individuals per year in the United States — with insurance benefit design identified as a significant structural barrier to care.

• Nutritional deficiencies and postoperative complications in surgical patients. Bariatric procedures, including sleeve gastrectomy and Roux-en-Y gastric bypass, predispose patients to nutritional deficiencies that can progress to haematological, muscular, neurological, and skeletal complications if untreated. Early postoperative complications include bleeding, venous thromboembolism, and anastomotic leakage, while late complications encompass dumping syndrome, marginal ulcers, and vitamin deficiencies — necessitating rigorous long-term follow-up.

• Educational gaps and misaligned perceptions impeding multimodal care. Survey data from 1,007 people with obesity and 474 healthcare providers indicate that both groups emphasize lifestyle change and individual responsibility, while educational gaps persist regarding the effectiveness and safety of newer antiobesity medications. These gaps represent a barrier to the recommended multimodal chronic care approach combining pharmacotherapy with HCP-guided lifestyle intervention.

VK2735-102: Positive Topline Results for Weight Loss Maintenance

Recent clinical and preclinical research has advanced the obesity pharmacotherapy landscape across multiple drug classes, from established GLP-1 receptor agonists to novel multi-agonist molecules. The studies below highlight key efficacy and safety findings across interventions evaluated in adults with overweight or obesity without diabetes.

VK2735 Demonstrates Excellent Tolerability in Maintenance Dosing Regimens

The VENTURE study (NCT06068946) — a Phase 2, randomized, double-blind, placebo-controlled, 13-week, dose-ranging trial of weekly subcutaneous VK2735 in adults with obesity or overweight and at least one weight-related comorbidity — provides the available published safety and tolerability data for VK2735. The adverse event (AE) profile was primarily gastrointestinal, and reported frequency of these AEs decreased after dose titration to steady state.

The knowledge base does not have sufficient information on this aspect.

VK2735's Differentiated Potential in the Obesity Treatment Landscape

VK2735 is a GLP-1/GIP receptor dual agonist under investigation for weight management in adults with obesity or overweight. Several other agents sharing this dual GIP/GLP-1 receptor agonist mechanism of action are also being evaluated for obesity and related metabolic indications, with tirzepatide representing the most clinically advanced comparator.

The knowledge base does not have sufficient information on this aspect.

VK2735: Reshaping Long-Term Obesity Care with Flexible Dosing

The recent positive topline results from Viking Therapeutics' maintenance study for VK2735, a dual GLP-1/GIP receptor agonist, represent a pivotal moment in the evolving landscape of obesity treatment. While the initial Phase 2 VENTURE study already demonstrated significant weight reduction with weekly dosing, the new data highlight the drug's ability to sustain this weight loss with remarkably less frequent subcutaneous injections—monthly or every-other-week. This is not merely a convenience factor; it's a potential game-changer for patient adherence in a chronic condition where long-term commitment is essential.

Maintaining up to 97% of mean weight loss with every-other-week dosing and 90% with monthly dosing, significantly outperforming placebo, addresses a critical challenge in obesity management. The excellent tolerability observed during the 12-week maintenance phase, with gastrointestinal adverse event rates comparable to placebo, further strengthens VK2735's profile. This could translate into improved patient quality of life and reduced treatment discontinuation, offering a compelling differentiator in a market increasingly populated by effective, but often weekly, injectable therapies.

However, several considerations remain. While the maintenance phase showed good tolerability, the initial dose titration period, as seen in the VENTURE study, did report common gastrointestinal adverse events. Managing these initial side effects will be crucial for patient onboarding and retention. Furthermore, while incretin-based therapies are increasingly recognized for their broader cardiometabolic benefits, including blood pressure reduction and improved cardiovascular outcomes, this specific maintenance study focused on weight maintenance. Future studies demonstrating these additional benefits will be vital for VK2735 to fully compete and establish its comprehensive value proposition. The ability to offer sustained weight loss with a flexible, less frequent dosing schedule positions VK2735 as a strong contender, potentially reshaping expectations for long-term obesity care.